{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:11:25Z","timestamp":1760058685419,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Almost all patients undergoing dialysis develop renal anemia and receive medicines such as erythropoietin and iron preparations. However, the conventional intravenous treatment with saccharated ferric oxide (SFO) is insufficient for these patients when they have incurable and persistent iron deficiency anemia due to secondary amyloidosis. Therefore, we administered 500 mg of ferric carboxymaltose (FCM) to such a patient with Crohn\u2019s disease. Case presentation: A 56-year-old man on maintenance hemodialysis had secondary amyloidosis due to Crohn\u2019s disease. Additionally, he was anemic and received 40 mg of SFO weekly; however, his hemoglobin (Hb) level remained low at 7 g\/dL. Therefore, 500 mg of FCM was administered bimonthly from the first to the fourth dose, and the Hb level temporarily increased compared to that after the previous SFO administration. Since bimonthly administration did not adequately maintain the Hb level, FCM was administered monthly from the 5th to 12th dose, which stabilized the Hb level at 10\u201312 g\/dL. No side effects, such as hypophosphatemia, were observed. Conclusions: A single dose of 500 mg FCM administered once every 1\u20132 months stabilizes the Hb level and contributes to efficient iron utilization in patients with incurable anemia undergoing hemodialysis.<\/jats:p>","DOI":"10.3390\/diseases13040125","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T04:57:11Z","timestamp":1745211431000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient with Secondary Amyloidosis Due to Crohn\u2019s Disease on Hemodialysis Effectively Treated with Ferric Carboxymaltose Injections: A Case Report and Literature Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Masayo","family":"Ueno","sequence":"first","affiliation":[{"name":"Department of Blood Purification, Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka 810-0044, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-5675","authenticated-orcid":false,"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Fuji","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka 810-0044, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka 810-0044, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Uemoto","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka 810-0044, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Rheumatology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-6400","authenticated-orcid":false,"given":"Takao","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Sanko Clinic, 4-9-3 Ropponmatsu, Chuo-ku, Fukuoka 810-0044, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000343398","article-title":"Renal involvement in AA amyloidosis: Clinical outcomes and survival","volume":"37","author":"Yilmaz","year":"2013","journal-title":"Kidney Blood Press Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.31486\/toj.20.0129","article-title":"Renal amyloidosis and Crohn disease","volume":"21","author":"Morales","year":"2021","journal-title":"Ochsner. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/msj.21342","article-title":"AA amyloidosis: Mount Sinai experience, 1997\u20132012","volume":"79","author":"Bunker","year":"2012","journal-title":"Mt. Sinai J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ecco-jcc\/jjv138","article-title":"Renal involvement in inflammatory bowel diseases","volume":"10","author":"Corica","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Avni, T., Bieber, A., Steinmetz, T., Leibovici, L., and Gafter-Gvili, A. (2013). Treatment of anemia in inflammatory bowel disease- Systematic review and meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075540"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2020.01.021","article-title":"Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team","volume":"304","author":"Pelliccia","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14740\/cr496w","article-title":"Cardiac amyloidosis masked as hypertrophic cardiomyopathy: A case report","volume":"7","author":"Wang","year":"2016","journal-title":"Cardiol. Res."},{"key":"ref_9","first-page":"205","article-title":"Clinical differences between transthyretin cardiac amyloidosis and hypertensive heart disease","volume":"162","year":"2024","journal-title":"Med. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10157-012-0694-3","article-title":"Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?","volume":"16","author":"Nakanishi","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-87-6-710","article-title":"Iron balance in hemodialysis patients","volume":"87","author":"Eschbach","year":"1977","journal-title":"Ann. Intern Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"763576","DOI":"10.1155\/2015\/763576","article-title":"Intravenous iron therapy in patients with iron deficiency anemia: Dosingng considerations","volume":"2015","author":"Koch","year":"2015","journal-title":"Anemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"Japanese society for dialysis therapy: Guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Ren. Replace Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1525-139X.2012.01089.x","article-title":"Red blood cell transfusion risks in patients with end-stage renal disease","volume":"25","author":"Tanhehco","year":"2012","journal-title":"Semin. Dial."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000183257","article-title":"Chloride-induced increase of plasma potassium after transfusion of erythrocytes in dialysis patients","volume":"37","author":"Schlarmann","year":"1984","journal-title":"Nephron"},{"key":"ref_16","first-page":"362","article-title":"Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: A dose-escalation study in volunteers with mild iron-deficiency anaemia","volume":"60","author":"Geisser","year":"2010","journal-title":"Arzneim. Forsch."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","article-title":"The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study","volume":"25","author":"Covic","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hofman, J.M.G., Eisenga, M.F., Diepenbroek, A., Nolte, I.M., van Dam, B., Westerhuis, R., Bakker, S.J.L., Franssen, C.F.M., and Gaillard, C.A.J.M. (2018). Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1045-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.23876\/j.krcp.20.015","article-title":"Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up","volume":"39","author":"Lacquaniti","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/1744-9987.13488","article-title":"Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center","volume":"24","author":"Gobbi","year":"2020","journal-title":"Ther. Apher. Dial."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rosati, A., Conti, P., Berto, P., Molinaro, S., Baldini, F., Egan, C.G., and Panichi, V. (2022). Efficacy, safety and pharmacoeconomic analysis of intravenous ferric carboxymaltose in anemic hemodialysis patients unresponsive to ferric gluconate treatment: A multicenter retrospective study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11185284"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ckj\/sfz153","article-title":"Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: An observational study","volume":"14","author":"Paraiso","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Diebold, M., and Kistler, A.D. (2019). Evaluation of iron stores in hemodialysis patients on maintenance ferric carboxymaltose dosing. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1263-8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI21441","article-title":"Anemia of inflammation: The cytokine-hepcidin link","volume":"113","author":"Andrews","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fang, W., Kenny, R., Rizvi, Q.U.A., McMahon, L.P., and Garg, M. (2020). Hypophosphataemia after ferric carboxymaltose in unrelated to symptoms, intestinal inflammation or vitamin D status. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01298-9"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/4\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:18:38Z","timestamp":1760030318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/4\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["diseases13040125"],"URL":"https:\/\/doi.org\/10.3390\/diseases13040125","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}